Lupin has associated with Mylan to commercialize Enbrel biosimilar.
Enbrel is a TNF-inhibitori suggested to treat certain autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
In a release the company stated that, as per the partnership agreement Mylan will commercialize Lupin’s proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.
Moreover, Vinita Gupta, CEO, Lupin stated, “We are extremely pleased to announce this partnership as both Lupin and Mylan share a commitment to bring affordable and high quality medicines to market, especially in areas of unmet need.”
